💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tamoxifen

CHEMBL83 Phase 4 承認済み Small molecule
Half-Life
5-7 days
Bioavailability
—
Protein Binding
—
Molecular Weight
371.5 g/mol
LogP
7.1
Phase
4

Tissue-selective behaviour is what makes tamoxifen a selective estrogen receptor modulator rather than a simple antagonist: it blocks estrogen receptors in breast tissue while exerting estrogen-like effects elsewhere, notably on the endometrium, which is the basis for gynaecological surveillance during treatment. In hormone receptor-positive breast cancer the antagonist action both treats established disease and reduces the risk of new disease, in men as well as women, with adjuvant courses conventionally extending over five to ten years. Its elimination half-life of five to seven days suits that prolonged use. Warfarin is recorded as a major interaction. The compound is C26H29NO, about 371.5 g/mol.

This medication blocks estrogen receptors in breast tissue and is widely used to treat and reduce the risk of hormone receptor-positive breast cancer in both women and men. It is typically taken as a daily tablet for five to ten years as part of a long-term cancer prevention or treatment plan. Regular gynecologic check-ups are recommended because it can have estrogen-like effects on the uterus.

分子量

371.5150 g/mol

LogP

7.10

TPSA

12.50 Ų

リピンスキーの五則

適合

治療領域

Oncology Breast Cancer

薬物分類

L — L - Antineoplastic and Immunomodulating Agents

Pharmacokinetics (PK)

Half-Life 5-7 days

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1

                

                

                
                

                    
InChI

                    
InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-

                

                

                

                    
                    

                        
Molecular Formula

                        
C26H29NO

                    

                    
                    

                        
HBD / HBA

                        
- / 2

                    

                    
                    

                        
回転可能結合数

                        
8

                    

                    
                    
                    

                        
重原子数

                        
28

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            CYP2D6 (Cytochrome P450 2D6)
                            Substrate
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Tamoxifen + Warfarin
                            
                        

                        
                        
Tamoxifen dramatically increases warfarin anticoagulation, causing large INR elevations and a substantially elevated risk of serious bleeding.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
This medication blocks estrogen receptors in breast tissue and is widely used to treat and reduce the risk of hormone receptor-positive breast cancer in both women and men. It is typically taken as a daily tablet for five to ten years as part of a long-term cancer prevention or treatment plan. Regular gynecologic check-ups are recommended because it can have estrogen-like effects on the uterus.

                        

                    

                    

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Tamoxifen: Half-life: 5-7 days.

                        

                    

                    

                    

                        
                        

                            
Yes, Tamoxifen is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Methotrexate
                            Small molecule
                        
                        
                        
                            Cyclosporine
                            Protein
                        
                        
                        
                            Tacrolimus
                            Small molecule
                        
                        
                        
                            Adalimumab
                            Antibody
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL83.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 2733526.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.